Tscan Therapeutics Inc
(TCRX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 536 | 566 | 7,211 | 3,887 | 3,148 |
| Gross Profit | 536 | 566 | 7,211 | 3,887 | 3,148 |
| Operating Expenses | 34,650 | 31,939 | 28,568 | 28,635 | 27,758 |
| Operating Income | -34,114 | -31,373 | -21,357 | -24,748 | -24,610 |
| Interest Expense | 952 | 959 | 852 | 982 | 969 |
| Other Income | 3,405 | 2,190 | 2,596 | 2,733 | 1,534 |
| Pre-tax Income | -31,661 | -30,142 | -19,613 | -22,997 | -24,045 |
| Net Income Continuous | -31,661 | -30,142 | -19,613 | -22,997 | -24,045 |
| Net Income | $-31,661 | $-30,142 | $-19,613 | $-22,997 | $-24,045 |
| EPS Basic Total Ops | -0.28 | -0.32 | 0.32 | -0.24 | -0.51 |
| EPS Basic Continuous Ops | -0.28 | -0.32 | 0.32 | -0.24 | -0.51 |
| EPS Diluted Total Ops | -0.28 | -0.32 | 0.32 | -0.24 | -0.51 |
| EPS Diluted Continuous Ops | -0.28 | -0.32 | 0.32 | -0.24 | -0.51 |
| EPS Diluted Before Non-Recurring Items | -0.28 | -0.32 | -0.21 | N/A | N/A |
| EBITDA(a) | $-32,998 | $-30,119 | $-20,077 | $-23,462 | $-23,314 |